MBD2 deficiency does not accelerate p53 mediated lymphomagenesis
Open Access
- 14 February 2005
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 24 (14) , 2430-2432
- https://doi.org/10.1038/sj.onc.1208166
Abstract
Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.Keywords
This publication has 12 references indexed in Scilit:
- Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation"Science, 2003
- Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivoCarcinogenesis: Integrative Cancer Research, 2003
- Deficiency of Mbd2 suppresses intestinal tumorigenesisNature Genetics, 2003
- An Unstable LiaisonScience, 2003
- Induction of Tumors in Mice by Genomic HypomethylationScience, 2003
- Chromosomal Instability and Tumors Promoted by DNA HypomethylationScience, 2003
- Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient backgroundOncogene, 2002
- P53 null mice: damaging the hypothesis?Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000
- Suppression of intestinal neoplasia by DNA hypomethylationCell, 1995
- Targeted mutation of the DNA methyltransferase gene results in embryonic lethalityPublished by Elsevier ,1992